Using light to diagnose kidney disease
Part of Hormones & metabolism, Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial uses a special light technique (Raman spectroscopy) to help diagnose different types of kidney disease. It may provide a faster, less invasive way to understand your condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have been diagnosed with one of these kidney diseases: IgA nephropathy, membranous nephropathy, diabetic nephropathy, or focal segmental glomerulosclerosis (confirmed by a kidney biopsy).
- You have not taken hormone therapy or immunosuppressant drugs before your kidney biopsy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at blood samples from people with kidney problems to learn more about the condition and find better ways to treat it.
This trial tests an experimental tablet, HSK39297, for people with IgA nephropathy, a kidney disease. It aims to see if the drug is safe and can help reduce protein in the urine, which is a sign of kidney damage.
This trial tests a personalized approach that uses a blood test to help guide targeted therapies for IgA nephropathy and IgA vasculitis. It may help reduce kidney damage and control the disease with fewer side effects.
This trial tests a new medication for IgA nephropathy, a kidney disease that causes inflammation and protein loss in urine. It aims to see if the drug can safely slow down kidney damage and protect kidney function.
This trial tests a new cell therapy called GT719 that targets B cells, part of the immune system that attacks the kidneys in several types of autoimmune kidney disease. It is designed for people whose kidney disease has not improved with standard treatments.
This trial looks at how bacteria in the gut (microbiome) and substances in the body (metabonomics) relate to IgA nephropathy, a kidney condition. The goal is to understand patterns that may help explain the disease and improve future care.
Hear when a new IgA Nephropathy (IgAN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.